

Dear Editors and Reviewers,

Thank you for your letter and for the reviewers' comments concerning our manuscript entitled "Potent BET Inhibitor JAB-8263 Suppresses MYC Expression and Exerts Anti-tumor Activity in Colorectal Cancer Models" (ID:81600). These comments were all valuable and very helpful for revising and improving our manuscript, as well as guiding the significance of our research. We have studied the comments carefully and have made corrections that we hope meet with approval. The revised portions are marked in red in the paper.

The main corrections in the paper and the responses to the reviewer's comments are as follows:

Responds to the reviewer's comments:

1. There are some typing errors.

Response: Thank you for this kind advice. We revised some typing errors.

2. The limitations of this study need to be mentioned and discussed.

Response: Thank you for this kind advice. In the last paragraph of "Discussion", we discussed the limitations of this study and the work needed in the future.

3. The reference type needs to be revised according to journal guideline.

Response: Thank you for this kind advice. We have updated the format of references according to journal guideline.

4. About the research progress of BET inhibitor JAB-8263 in the Paragraph 3 of "Introduction" should be cited the related literature.

Response: Thank you for this kind advice. JAB-8263 is a new BET inhibitor. This is the first time that it has been reported. At present, there is no public data.

5. All images of Figure 1 should be more clear.

Response: Thank you for this kind advice. We uploaded new Figure 1 in PPT file.